Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
The highest-volume laparoscopic cases; identifies every active general surgeon. Main billing specialty: general surgery.
Medicare fee-for-service cholecystectomy & appendectomy cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 221 | 11,459−2.6%/yr | −2.6%/yr | 3.50.8× | 2% | 12,600 in 2030+1.6%/yr |
| Texas | 216 | 9,832−5.4%/yr | −5.4%/yr | 4.71.1× | 4% | 10,900 in 2030+1.7%/yr |
| Florida | 212 | 9,319−5.5%/yr | −5.5%/yr | 4.31.0× | 1% | 10,300 in 2030+1.7%/yr |
| New York | 96 | 5,762−3.7%/yr | −3.7%/yr | 3.30.8× | 2% | 6,020 in 2030+0.7%/yr |
| Pennsylvania | 95 | 5,634−4%/yr | −4%/yr | 4.31.0× | 1% | 5,840 in 2030+0.6%/yr |
| Illinois | 106 | 4,982−6.5%/yr | −6.5%/yr | 3.70.9× | 2% | 5,420 in 2030+1.4%/yr |
| Ohio | 70 | 4,777−4.3%/yr | −4.3%/yr | 4.51.1× | 1% | 5,070 in 2030+1%/yr |
| North Carolina | 77 | 4,307−7.3%/yr | −7.3%/yr | 4.51.1× | 2% | 4,130 in 2030−0.7%/yr |
| Georgia | 78 | 3,999−6.7%/yr | −6.7%/yr | 4.81.1× | 0% | 4,290 in 2030+1.2%/yr |
| Virginia | 74 | 3,844−4.8%/yr | −4.8%/yr | 3.70.9× | 1% | 4,110 in 2030+1.1%/yr |
| Tennessee | 81 | 3,433−6.8%/yr | −6.8%/yr | 5.01.2× | 4% | 3,630 in 2030+0.9%/yr |
| New Jersey | 81 | 3,400−3.2%/yr | −3.2%/yr | 3.30.8× | 1% | 3,540 in 2030+0.7%/yr |
| Arizona | 74 | 3,384−3.1%/yr | −3.1%/yr | 4.71.1× | 5% | 3,490 in 2030+0.5%/yr |
| Michigan | 39 | 3,319−9.3%/yr | −9.3%/yr | 4.11.0× | 1% | 3,010 in 2030−1.6%/yr |
| Indiana | 69 | 3,309−4.8%/yr | −4.8%/yr | 4.81.2× | 5% | 3,260 in 2030−0.3%/yr |
| Missouri | 76 | 3,242−6.5%/yr | −6.5%/yr | 5.41.3× | 2% | 3,240 in 20300%/yr |
| Massachusetts | 60 | 3,162−3.7%/yr | −3.7%/yr | 3.40.8× | 0% | 3,520 in 2030+1.8%/yr |
| South Carolina | 65 | 2,781−5.5%/yr | −5.5%/yr | 4.21.0× | 1% | 3,300 in 2030+2.9%/yr |
| Washington | 31 | 2,636−5.6%/yr | −5.6%/yr | 3.50.8× | 2% | 2,630 in 20300%/yr |
| Kentucky | 56 | 2,519−8.1%/yr | −8.1%/yr | 5.71.4× | 1% | 2,490 in 2030−0.2%/yr |
| Maryland | 54 | 2,461−3.8%/yr | −3.8%/yr | 2.80.7× | 6% | 2,750 in 2030+1.9%/yr |
| Wisconsin | 20 | 2,445−4.2%/yr | −4.2%/yr | 4.51.1× | 1% | 2,580 in 2030+0.9%/yr |
| Oklahoma | 64 | 2,262−6.3%/yr | −6.3%/yr | 4.81.1× | 0% | 2,230 in 2030−0.3%/yr |
| Louisiana | 56 | 2,158−8.2%/yr | −8.2%/yr | 5.41.3× | 3% | 2,120 in 2030−0.3%/yr |
| Alabama | 49 | 2,132−10%/yr | −10%/yr | 5.01.2× | 4% | 1,870 in 2030−2.2%/yr |
| Arkansas | 59 | 2,014−6.1%/yr | −6.1%/yr | 5.51.3× | 3% | 1,900 in 2030−0.9%/yr |
| Minnesota | 23 | 1,976−5.3%/yr | −5.3%/yr | 4.51.1× | 2% | 2,420 in 2030+3.5%/yr |
| Colorado | 18 | 1,923−3.3%/yr | −3.3%/yr | 4.11.0× | 3% | 2,250 in 2030+2.6%/yr |
| Mississippi | 52 | 1,864−9.9%/yr | −9.9%/yr | 5.11.2× | 7% | 1,780 in 2030−0.8%/yr |
| Kansas | 50 | 1,841−5.1%/yr | −5.1%/yr | 4.61.1× | 5% | 1,870 in 2030+0.2%/yr |
| Iowa | 36 | 1,637−4.5%/yr | −4.5%/yr | 3.80.9× | 4% | 1,650 in 2030+0.2%/yr |
| Oregon | 12 | 1,552−4.6%/yr | −4.6%/yr | 3.80.9× | 1% | 1,830 in 2030+2.8%/yr |
| Nebraska | 33 | 1,242−5.8%/yr | −5.8%/yr | 4.91.2× | 7% | 1,320 in 2030+1%/yr |
| Nevada | 21 | 1,144−2.4%/yr | −2.4%/yr | 4.11.0× | 0% | 1,330 in 2030+2.6%/yr |
| Connecticut | 13 | 1,125−6.5%/yr | −6.5%/yr | 3.50.8× | 0% | 1,160 in 2030+0.5%/yr |
| Utah | 13 | 952−6.8%/yr | −6.8%/yr | 4.51.1× | 2% | 1,140 in 2030+3%/yr |
| Idaho | 14 | 858−2.1%/yr | −2.1%/yr | 4.31.0× | 0% | 1,150 in 2030+5%/yr |
| West Virginia | 19 | 820−11%/yr | −11%/yr | 4.01.0× | 0% | 720 in 2030−2.2%/yr |
| New Hampshire | 6 | 766−3%/yr | −3%/yr | 3.40.8× | 2% | 990 in 2030+4.4%/yr |
| New Mexico | 9 | 736−6.4%/yr | −6.4%/yr | 3.30.8× | 0% | 870 in 2030+2.8%/yr |
| Montana | 9 | 685−6%/yr | −6%/yr | 3.70.9× | 2% | 740 in 2030+1.2%/yr |
| South Dakota | 11 | 645−6.4%/yr | −6.4%/yr | 5.11.2× | 0% | 750 in 2030+2.6%/yr |
| Delaware | 14 | 605−4.5%/yr | −4.5%/yr | 3.60.9× | 0% | 740 in 2030+3.5%/yr |
| Maine | 3 | 578−9.6%/yr | −9.6%/yr | 3.80.9× | 0% | 630 in 2030+1.4%/yr |
| North Dakota | 6 | 502−6.4%/yr | −6.4%/yr | 5.11.2× | 0% | 570 in 2030+2.2%/yr |
| Alaska | 3 | 396−0.7%/yr | −0.7%/yr | 3.30.8× | 0% | 500 in 2030+3.8%/yr |
| Rhode Island | 4 | 359−3.4%/yr | −3.4%/yr | 4.11.0× | 0% | 360 in 2030−0.1%/yr |
| Wyoming | 4 | 353−6.8%/yr | −6.8%/yr | 3.30.8× | 6% | 390 in 2030+1.8%/yr |
| District of Columbia | 4 | 315−2.4%/yr | −2.4%/yr | 5.11.2× | 2% | 340 in 2030+1.3%/yr |
| Hawaii | 2 | 277−3.2%/yr | −3.2%/yr | 2.20.5× | 0% | 360 in 2030+4.7%/yr |
| Vermont | 2 | 272−7%/yr | −7%/yr | 2.40.6× | 0% | 430 in 2030+8%/yr |
Professional codes (what the surgeon bills): CPT 47562, 47563, 44970, 47600; the hospital bills MS-DRG 417, 418, 419, 338, 339, 340, 397, 398, 399.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 310 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 132 companies. The most active:
Product codes: GAG (stapler, surgical), GCJ (laparoscope, general & plastic surgery), GDW (staple, implantable). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 11% of the cases CMS names in California; 154 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Hernia repair | 2,306 | 187,629−3%/yr | −3%/yr | 210,200 in 2030+1.9%/yr |
| Colorectal resection | 232 | 52,254−5.2%/yr | −5.2%/yr | 53,600 in 2030+0.4%/yr |
| Antireflux & hiatal hernia surgery | 375 | 23,396−1.8%/yr | −1.8%/yr | 28,800 in 2030+3.5%/yr |
| Breast reconstruction | 66 | 13,660−6.4%/yr | −6.4%/yr | 17,400 in 2030+4.1%/yr |
| Bariatric surgery | 15 | 4,952−17%/yr | −17%/yr | 3,750 in 2030−4.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 14 companies reported engagement with surgeons in the covered states worth $3.1M in consulting, speaking, meals and travel tied to these products, about $1,227 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 33 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.